Last update 17 Jun 2025

68Ga-FAPI-RGD PET-CT

Overview

Basic Info

Drug Type
Diagnostic radiopharmaceuticals, Radionuclide Drug Conjugates (RDC)
Synonyms-
Target-
Action
enhancers
Mechanism
PET imaging(Positron-emission tomography enhancers)
Therapeutic Areas
NeoplasmsCongenital DisordersDigestive System Disorders+ [1]
Active Indication
Adenomatous Polyposis ColiNeoplasm Metastasis
Inactive Indication-
Originator Organization-
Active Organization
Peking Union Medical College Hospital
Inactive Organization-
License Organization-
Drug Highest PhaseEarly Phase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

3
Clinical Trials associated with 68Ga-FAPI-RGD PET-CT
ChiCTR2500096350
/ SuspendedNot ApplicableIIT
68Ga-FAPI-RGD PET/CT or 18F-AlF-FAPI-RGD PET/CT in the diagnosis of malignant tumors: a cross-sectional, diagnostic clinical study
NCT06638034
/ RecruitingEarly Phase 1IIT
Diagnosis of Metastatic Tumors on 68Ga-FAPI-RGD PET-CT and Radioligand Therapy
NCT05543954
/ RecruitingEarly Phase 1IIT
A Pilot Study of 68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients
100 Clinical Results associated with 68Ga-FAPI-RGD PET-CT
Login to view more data
100 Translational Medicine associated with 68Ga-FAPI-RGD PET-CT
Login to view more data
100 Patents (Medical) associated with 68Ga-FAPI-RGD PET-CT
Login to view more data
100 Deals associated with 68Ga-FAPI-RGD PET-CT
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Adenomatous Polyposis ColiPhase 1
China
Peking Union Medical College Hospital
01 May 2024
Neoplasm MetastasisPhase 1
China
Peking Union Medical College Hospital
01 May 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
SNMMI2023
Not Applicable
Neoplasms
-
(18F-FDG PET/CT)
zeimwrvpvv(huypqcvuzm) = zyxrjtcurd eilggsowtt (hzevfpxzka )
-
28 Aug 2023
SNMMI2023
Not Applicable
Lung Cancer
-
(18F-FDG PET/CT)
jsveyqrwbv(mzllfcxfrk) = 68Ga-FAPI-RGD was well tolerated, with no adverse events reported in correlation with the study in any of the patient bkjirsvwap (leicblykwd )
-
28 Aug 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free